Avid Bioservices Inc (CDMO)

[vinmantoo]

PPHM's Bavituximab and new BetaBodies however CAPS PS itself thereby disabling it from binding with all 12 PS receptors at ones and hence avoid not only suppression by the immune system but also stimulates the immune system to activate (which is a requirement).

As usual, you ignore the major drawbacks and red flags of the anti-PS approach as compared to the anti-receptor or anti-Ligand approach. There are orders of magnitude more PS (100-1000x) on the tumor cell surface than any receptor (or immune cell) or ligand on the tumor cell. This means a of of free PS will still be there for receptors or ligands to bind. Second, the receptor or ligand approach has already shown enough efficacy as a single agent to merit FDA approval in multiple different cancers, whereas Bavi has failed to do so. Third, there is a large sink of PS on apoptotic cells, especially true for cancer patients, which tend to be older. This draws off Bavi from its intended target, hindering an chances for therapeutic effects.